122 related articles for article (PubMed ID: 37207419)
1. Enhanced lysosomal escape of cell penetrating peptide-functionalized metal-organic frameworks for co-delivery of survivin siRNA and oridonin.
Cai M; Yao Y; Yin D; Zhu R; Fu T; Kong J; Wang K; Liu J; Yao A; Ruan Y; Shi W; Zhu Q; Ni J; Yin X
J Colloid Interface Sci; 2023 Sep; 646():370-380. PubMed ID: 37207419
[TBL] [Abstract][Full Text] [Related]
2. Smart polymeric nanoparticles with pH-responsive and PEG-detachable properties for co-delivering paclitaxel and survivin siRNA to enhance antitumor outcomes.
Jin M; Jin G; Kang L; Chen L; Gao Z; Huang W
Int J Nanomedicine; 2018; 13():2405-2426. PubMed ID: 29719390
[TBL] [Abstract][Full Text] [Related]
3. Selective Cell Penetrating Peptide-Functionalized Envelope-Type Chimeric Lipopepsomes Boost Systemic RNAi Therapy for Lung Tumors.
Qiu M; Ouyang J; Wei Y; Zhang J; Lan Q; Deng C; Zhong Z
Adv Healthc Mater; 2019 Aug; 8(16):e1900500. PubMed ID: 31231966
[TBL] [Abstract][Full Text] [Related]
4. Enhanced Lysosomal Escape of pH-Responsive Polyethylenimine-Betaine Functionalized Carbon Nanotube for the Codelivery of Survivin Small Interfering RNA and Doxorubicin.
Cao Y; Huang HY; Chen LQ; Du HH; Cui JH; Zhang LW; Lee BJ; Cao QR
ACS Appl Mater Interfaces; 2019 Mar; 11(10):9763-9776. PubMed ID: 30776886
[TBL] [Abstract][Full Text] [Related]
5. Aperture Modulation of Isoreticular Metal Organic Frameworks for Targeted Antitumor Drug Delivery.
Cai M; Liang W; Wang K; Yin D; Fu T; Zhu R; Qu C; Dong X; Ni J; Yin X
ACS Appl Mater Interfaces; 2022 Aug; 14(32):36366-36378. PubMed ID: 35897121
[TBL] [Abstract][Full Text] [Related]
6. Cell-Penetrating Peptide-Modified Graphene Oxide Nanoparticles Loaded with Rictor siRNA for the Treatment of Triple-Negative Breast Cancer.
Yang YY; Zhang W; Liu H; Jiang JJ; Wang WJ; Jia ZY
Drug Des Devel Ther; 2021; 15():4961-4972. PubMed ID: 34916779
[TBL] [Abstract][Full Text] [Related]
7. Smart Polymeric Nanoparticles with pH-Responsive and PEG-Detachable Properties (II): Co-Delivery of Paclitaxel and VEGF siRNA for Synergistic Breast Cancer Therapy in Mice.
Jin M; Hou Y; Quan X; Chen L; Gao Z; Huang W
Int J Nanomedicine; 2021; 16():5479-5494. PubMed ID: 34413645
[TBL] [Abstract][Full Text] [Related]
8. Design and anti-tumor activity of self-loaded nanocarriers of siRNA.
Han W; Yuan Y; Li H; Fu Z; Wang M; Guan S; Wang L
Colloids Surf B Biointerfaces; 2019 Nov; 183():110385. PubMed ID: 31408781
[TBL] [Abstract][Full Text] [Related]
9. Chitosan-based nanoparticles for survivin targeted siRNA delivery in breast tumor therapy and preventing its metastasis.
Sun P; Huang W; Jin M; Wang Q; Fan B; Kang L; Gao Z
Int J Nanomedicine; 2016; 11():4931-4945. PubMed ID: 27729789
[TBL] [Abstract][Full Text] [Related]
10. Combination antitumor immunotherapy with VEGF and PIGF siRNA via systemic delivery of multi-functionalized nanoparticles to tumor-associated macrophages and breast cancer cells.
Song Y; Tang C; Yin C
Biomaterials; 2018 Dec; 185():117-132. PubMed ID: 30241030
[TBL] [Abstract][Full Text] [Related]
11. Combination Therapy of Breast Cancer by Codelivery of Doxorubicin and Survivin siRNA Using Polyethylenimine Modified Silk Fibroin Nanoparticles.
Norouzi P; Motasadizadeh H; Atyabi F; Dinarvand R; Gholami M; Farokhi M; Shokrgozar MA; Mottaghitalab F
ACS Biomater Sci Eng; 2021 Mar; 7(3):1074-1087. PubMed ID: 33539074
[TBL] [Abstract][Full Text] [Related]
12. CaP coated mesoporous polydopamine nanoparticles with responsive membrane permeation ability for combined photothermal and siRNA therapy.
Wang Z; Wang L; Prabhakar N; Xing Y; Rosenholm JM; Zhang J; Cai K
Acta Biomater; 2019 Mar; 86():416-428. PubMed ID: 30611792
[TBL] [Abstract][Full Text] [Related]
13. Tumor-targeted pH/redox dual-sensitive unimolecular nanoparticles for efficient siRNA delivery.
Chen G; Wang Y; Xie R; Gong S
J Control Release; 2017 Aug; 259():105-114. PubMed ID: 28159516
[TBL] [Abstract][Full Text] [Related]
14. Oridonin-Loaded Nanoparticles Inhibit Breast Cancer Progression Through Regulation of ROS-Related Nrf2 Signaling Pathway.
Zhao Y; Xiao W; Peng W; Huang Q; Wu K; Evans CE; Liu X; Jin H
Front Bioeng Biotechnol; 2021; 9():600579. PubMed ID: 33898397
[TBL] [Abstract][Full Text] [Related]
15. Silencing of survivin and cyclin B1 through siRNA-loaded arginine modified calcium phosphate nanoparticles for non-small-cell lung cancer therapy.
Kara G; Parlar A; Cakmak MC; Cokol M; Denkbas EB; Bakan F
Colloids Surf B Biointerfaces; 2020 Dec; 196():111340. PubMed ID: 32956996
[TBL] [Abstract][Full Text] [Related]
16. Liposomal codelivery of an SN38 prodrug and a survivin siRNA for tumor therapy.
Bi Y; Lee RJ; Wang X; Sun Y; Wang M; Li L; Li C; Xie J; Teng L
Int J Nanomedicine; 2018; 13():5811-5822. PubMed ID: 30323583
[TBL] [Abstract][Full Text] [Related]
17. Dual-functionalized graphene oxide for enhanced siRNA delivery to breast cancer cells.
Imani R; Shao W; Taherkhani S; Emami SH; Prakash S; Faghihi S
Colloids Surf B Biointerfaces; 2016 Nov; 147():315-325. PubMed ID: 27543693
[TBL] [Abstract][Full Text] [Related]
18. Apoptosis induction activity and molecular docking studies of survivin siRNA carried by Fe
Arami S; Mahdavi M; Rashidi MR; Yekta R; Rahnamay M; Molavi L; Hejazi MS; Samadi N
J Pharm Biomed Anal; 2017 Aug; 142():145-154. PubMed ID: 28505590
[TBL] [Abstract][Full Text] [Related]
19. Cell-penetrating peptide-conjugated lipid nanoparticles for siRNA delivery.
Asai T; Tsuzuku T; Takahashi S; Okamoto A; Dewa T; Nango M; Hyodo K; Ishihara H; Kikuchi H; Oku N
Biochem Biophys Res Commun; 2014 Feb; 444(4):599-604. PubMed ID: 24486551
[TBL] [Abstract][Full Text] [Related]
20. Surface-modified nanoparticles enhance transurothelial penetration and delivery of survivin siRNA in treating bladder cancer.
Martin DT; Steinbach JM; Liu J; Shimizu S; Kaimakliotis HZ; Wheeler MA; Hittelman AB; Mark Saltzman W; Weiss RM
Mol Cancer Ther; 2014 Jan; 13(1):71-81. PubMed ID: 24222663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
